AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34993850 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 29
Study 34993850 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 29
Study 34994093 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days
Number of subjects: 95
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) measurements
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests (grip strength, 6 min walk test)
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockwood Clinical Frailty Scale (RCFS)
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE II combined with BIA and CT measurements
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Body cell mass derived by BIA
Number of subjects: 94
Study 34994094 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle area in CT scan (TPA/BSA)
Number of subjects: 94
Study 34994169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Eating Questionnaire (MEQ)
Number of subjects: 46
Study 34994169 — intervention group
Group type: EXPERIMENTAL
Intervention: Distracted eating behavior
Number of subjects: 46
Study 34994169 — intervention group
Group type: COMPARATOR
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 46
Study 34994234 — intervention group
Group type: EXPERIMENTAL
Intervention: POLARIS stent implantation
Number of subjects: 199
Study 34994306 — intervention group
Group type: EXPERIMENTAL
Intervention: SSEQ-DK (Stroke Self-Efficacy Questionnaire - Danish version)
Number of subjects: 50
Study 34994582 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 334
Study 34994617 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Vinorelbine
Number of subjects: 20
Study 34994777 — intervention group
Group type: EXPERIMENTAL
Intervention: ST266 eye drops, 4 times daily for 28 days
Number of subjects: 12
Study 34994968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34994968 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34995128 — intervention group
Group type: EXPERIMENTAL
Intervention: Early locoregional therapy (surgery and radiotherapy per standards for nonmetastatic disease)
Number of subjects: 390
Study 34995128 — intervention group
Group type: COMPARATOR
Intervention: Continued systemic therapy
Number of subjects: 390
Study 34995128 — intervention group
Group type: EXPERIMENTAL
Intervention: Early locoregional therapy
Number of subjects: 390
Study 34995204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, 4 sessions over 5 weeks
Number of subjects: 49
Study 34995204 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group for 28 weeks
Number of subjects: 49
Study 34995639 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe A
Number of subjects: 80
Study 34995639 — intervention group
Group type: COMPARATOR
Intervention: CADe B
Number of subjects: 80
Study 34995640 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided choledochoduodenostomy (EUS-CDS) with lumen-apposing metal stent (LAMS)
Number of subjects: 256
Study 34995719 — intervention group
Group type: EXPERIMENTAL
Intervention: INCRAFT AAA Stent Graft System
Number of subjects: 150
Study 34995818 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (CS) eye drops monitored with Kali Drop device
Number of subjects: 90
Study 34996114 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment for 6 weeks in addition to mood stabilizer
Number of subjects: 20
Study 34996114 — intervention group
Group type: COMPARATOR
Intervention: [11C]CUMI-101 BPF in bipolar participants
Number of subjects: 20
Study 34996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower and upper middle-income countries (LMIC)
Number of subjects: 9864
Study 34996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper middle-income countries (UMIC)
Number of subjects: 9864
Study 34996361 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income countries (HIC)
Number of subjects: 9864
Study 34996401 — intervention group
Group type: EXPERIMENTAL
Intervention: NICU acquires MOM (intervention)
Number of subjects: 284
Study 34996401 — intervention group
Group type: COMPARATOR
Intervention: mother provides MOM (control)
Number of subjects: 284
Study 34996465 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting/completing an ILD-related quality improvement project in the previous 2 years
Number of subjects: 27
Study 34996465 — intervention group
Group type: COMPARATOR
Intervention: Site-level characteristics or practices
Number of subjects: 27
Study 34996465 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 27
Study 34996465 — intervention group
Group type: COMPARATOR
Intervention: Death or lung transplant
Number of subjects: 27
Study 34996465 — intervention group
Group type: COMPARATOR
Intervention: Death
Number of subjects: 27
Study 34996516 — intervention group
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Number of subjects: 39
Study 34996516 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy
Number of subjects: 39
Study 34996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 52018
Study 34996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatments
Number of subjects: 52018
Study 34996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare Access and Quality indices
Number of subjects: 52018
Study 34996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of comorbidities and lifestyle factors
Number of subjects: 52018
Study 34996920 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAA)
Number of subjects: 0
Study 34996920 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon (peg-IFN)
Number of subjects: 0
Study 34997267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (55 mg elemental iron from ferrous sulphate, once daily for 3 months)
Number of subjects: 64
Study 34997268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pulmonary fibrosis and emphysema (CPFE)
Number of subjects: 934
Study 34997268 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic pulmonary fibrosis (IPF) alone
Number of subjects: 934
Study 34997316 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk-reducing salpingectomy with delayed oophorectomy
Number of subjects: 577
Study 34997316 — intervention group
Group type: COMPARATOR
Intervention: Standard risk-reducing salpingo-oophorectomy
Number of subjects: 577
Study 34997559 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose ciprofloxacin
Number of subjects: 2
Study 34997559 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing combined with microdialysis
Number of subjects: 2
Study 34997701 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (320 mg weekly)
Number of subjects: 0
Study 34997701 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (0.5 mg dose)
Number of subjects: 0
Study 34997701 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (1-10 mg/L) in Raji xenograft tumor mouse model
Number of subjects: 0
Study 34997701 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted human pharmacokinetic parameters from monkey data
Number of subjects: 0
Study 34997825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g
Number of subjects: 22
Study 34997825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g
Number of subjects: 22
Study 34997889 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/Etoposide/Vincristine (CarbEV)
Number of subjects: 158
Study 34997889 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/Etoposide/Vincristine (CycEV)
Number of subjects: 158
Study 34997889 — intervention group
Group type: EXPERIMENTAL
Intervention: Choroid Plexus Papilloma (CPP)
Number of subjects: 158
Study 34997889 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical Choroid Plexus Papilloma (APP)
Number of subjects: 158
Study 34997889 — intervention group
Group type: EXPERIMENTAL
Intervention: Choroid Plexus Carcinoma (CPC)
Number of subjects: 158
Study 34997889 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC younger than three years without irradiation
Number of subjects: 158
Study 34997984 — intervention group
Group type: EXPERIMENTAL
Intervention: Migration with mother
Number of subjects: 1238
Study 34997984 — intervention group
Group type: EXPERIMENTAL
Intervention: Migration without mother
Number of subjects: 1238
Study 34997984 — intervention group
Group type: COMPARATOR
Intervention: No migration
Number of subjects: 1238
Study 34998033 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily protein intake (DPI)
Number of subjects: 1035
Study 34998033 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI/kg BW
Number of subjects: 1035
Study 34998033 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI over time
Number of subjects: 1035
Study 34998033 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of protein intake
Number of subjects: 1035
Study 34998048 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib + Avelumab
Number of subjects: 34
Study 34998092 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-EGFR ILs-dox
Number of subjects: 3
Study 34998370 — intervention group
Group type: EXPERIMENTAL
Intervention: NightOwl™ home-monitoring device for sleep apnea
Number of subjects: 150
Study 34998370 — intervention group
Group type: COMPARATOR
Intervention: Standard evaluation method (CRM)
Number of subjects: 150
Study 34998377 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex PCR test plus autoimmune antibody testing
Number of subjects: 484
Study 34998377 — intervention group
Group type: COMPARATOR
Intervention: mNGS plus autoimmune antibody testing
Number of subjects: 484
Study 34998425 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular artery embolization
Number of subjects: 58
Study 34998425 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 58
Study 34998471 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg once every 2 weeks plus apatinib 250 mg once daily for a 28-day cycle
Number of subjects: 52
Study 34998471 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 52
Study 34998605 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant quadrivalent influenza vaccine (RIV4)
Number of subjects: 15774
Study 34998605 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4)
Number of subjects: 15774
Study 34998740 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-ECG at pulmonary valve position
Number of subjects: 1050
Study 34998740 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal combination of AI-ECG outputs from pulmonary and handheld positions
Number of subjects: 1050
Study 34998740 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted logistic regression with l2 regularisation using AI-ECG outputs from pulmonary and handheld positions
Number of subjects: 1050
Study 34998942 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic branched endografting (TBE)
Number of subjects: 55
Study 34998942 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization (SR-TEVAR)
Number of subjects: 55
Study 34998942 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mid-term survival
Number of subjects: 55
Study 34998942 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of device-related endoleak
Number of subjects: 55
Study 34998942 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of device-related reintervention
Number of subjects: 55
Study 34999223 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (PRO 140)
Number of subjects: 0
Study 34999322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Bariatric Prospective group
Number of subjects: 61
Study 34999322 — intervention group
Group type: COMPARATOR
Intervention: Control Prospective group
Number of subjects: 61
Study 34999322 — intervention group
Group type: COMPARATOR
Intervention: Control Bariatric Retrospective group
Number of subjects: 61
Study 34999563 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 outbreak period
Number of subjects: 246
Study 34999563 — intervention group
Group type: COMPARATOR
Intervention: Non COVID-19 outbreak period
Number of subjects: 246
Study 34999590 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes (PROs)
Number of subjects: 0
Study 34999590 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of PROs in clinical trials
Number of subjects: 0
Study 34999590 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interventional studies and registries
Number of subjects: 0
Study 34999590 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory consideration of PROs
Number of subjects: 0
Study 34999659 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in naive KTRs
Number of subjects: 736
Study 34999659 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in previously infected KTRs
Number of subjects: 736
Study 34999659 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate use
Number of subjects: 736
Study 34999659 — intervention group
Group type: COMPARATOR
Intervention: Depleting therapy in the past year
Number of subjects: 736
Study 34999659 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma release assay in naive KTRs
Number of subjects: 736
Study 34999659 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma release assay in previously infected KTRs
Number of subjects: 736
Study 34999659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination on the waiting list before transplantation
Number of subjects: 736
Study 34999667 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-tailored intervention focused on smoking cessation
Number of subjects: 0
Study 34999667 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention focused on smoking cessation
Number of subjects: 0
Study 34999843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disordered breathing (SDB) measured by respiratory event index (REI) and oxygen desaturation index (ODI)
Number of subjects: 192
Study 34999843 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosis (REI > 5 events per hour)
Number of subjects: 192
Study 34999843 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB
Number of subjects: 192
Study 35000058 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2-Comirnaty vaccination
Number of subjects: 31
Study 35000420 — intervention group
Group type: EXPERIMENTAL
Intervention: preCARDIA therapy for 12 or 24 hours
Number of subjects: 30
Study 35001023 — intervention group
Group type: EXPERIMENTAL
Intervention: ICEBERG score
Number of subjects: 207
Study 35001023 — intervention group
Group type: EXPERIMENTAL
Intervention: ICEBERG visual representation
Number of subjects: 207
Study 35001051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid/dextranomer treatment
Number of subjects: 283
Study 35001477 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ 670G system in Auto Mode
Number of subjects: 46
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door HIV testing services (HTS)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide 'Man-up' campaigns (IR1)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller HTS campaigns at work/social places (IR2)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Revisits to households with the option of HIV self-testing (HIVST) (IR3)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hubs offering HTS (after trial completion)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) during revisits (IR3)
Number of subjects: 0
Study 35001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Work/social place campaigns (IR2)
Number of subjects: 0
Study 35001562 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2126
Study 35001562 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 2126
Study 35002683 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35002791 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine treatment for 12 weeks
Number of subjects: 8
Study 35002935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence
Number of subjects: 0
Study 35002951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet items and diet score
Number of subjects: 3402
Study 35002951 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 3402
Study 35002951 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking to school
Number of subjects: 3402
Study 35003076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (CladT)
Number of subjects: 0
Study 35003094 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL1RAP antibody (nadunolimab, CAN04)
Number of subjects: 0
Study 35003094 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1RAcP targeting
Number of subjects: 0
Study 35003503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Administration of Auricular Acupuncture
Number of subjects: 0
Study 35004246 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality (AR) navigation-guided localization
Number of subjects: 4
Study 35004532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 35004718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription intervention; details not available
Number of subjects: 0
Study 35004719 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Uterine Cervical Traction Device
Number of subjects: 0
Study 35004914 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35005158 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD)
Number of subjects: 21
Study 35005312 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674
Study 35005359 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking at the needle
Number of subjects: 160
Study 35005359 — intervention group
Group type: COMPARATOR
Intervention: Looking away from the needle
Number of subjects: 160
Study 35005383 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature asymmetry (SkTA) measured using handheld infrared thermometers after cold pressor test (CPT)
Number of subjects: 65
Study 35005383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) involving immersion of a single foot in 5°C water for 30 seconds
Number of subjects: 65
Study 35005383 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers, known nerve injury, and hand fracture groups
Number of subjects: 65
Study 35005393 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral methadone
Number of subjects: 0
Study 35005393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35005411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based bibliotherapy intervention
Number of subjects: 0
Study 35005411 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35005428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0
Study 35005428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35005582 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 112
Study 35005654 — intervention group
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V) plus nivolumab
Number of subjects: 37
Study 35005701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention
Number of subjects: 0
Study 35005777 — intervention group
Group type: COMPARATOR
Intervention: Antifungal treatment (oral or topical)
Number of subjects: 2212
Study 35005777 — intervention group
Group type: COMPARATOR
Intervention: Oral drug treatment
Number of subjects: 2212
Study 35005777 — intervention group
Group type: COMPARATOR
Intervention: Adverse events (treatment and control groups)
Number of subjects: 2212
Study 35005781 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapies (including pharmacological therapies, dietary supplements, and complementary and alternative medicines) for prevention of AIMSS
Number of subjects: 2034
Study 35005781 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapies (including vitamin D, bionic tiger bone, Yi Shen Jian Gu granules, calcitonin) for treatment of AIMSS
Number of subjects: 2034
Study 35005800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE)
Number of subjects: 539
Study 35006026 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent or permanent AF
Number of subjects: 1052
Study 35006026 — intervention group
Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 1052
Study 35006026 — intervention group
Group type: COMPARATOR
Intervention: First diagnosed AF
Number of subjects: 1052
Study 35007144 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive T-Cell Depletion
Number of subjects: 138
Study 35007224 — intervention group
Group type: EXPERIMENTAL
Intervention: Groin hernia surgery in women
Number of subjects: 4021
Study 35007270 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic resection using the da Vinci Xi system with intraoperative neurostimulation mapping
Number of subjects: 3
Study 35007329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 1441